Rothschild Asset Management Inc. lowered its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 4.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,869 shares of the biotechnology company’s stock after selling 2,301 shares during the period. Rothschild Asset Management Inc. owned about 0.19% of Aclaris Therapeutics worth $1,380,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ACRS. FMR LLC raised its position in Aclaris Therapeutics by 253.1% in the first quarter. FMR LLC now owns 1,653,937 shares of the biotechnology company’s stock worth $49,321,000 after buying an additional 1,185,598 shares during the last quarter. Vanguard Group Inc. raised its position in Aclaris Therapeutics by 17.6% in the first quarter. Vanguard Group Inc. now owns 711,519 shares of the biotechnology company’s stock worth $21,218,000 after buying an additional 106,303 shares during the last quarter. MARSHALL WACE ASIA Ltd purchased a new position in Aclaris Therapeutics during the first quarter worth about $21,116,000. Marshall Wace North America L.P. purchased a new position in Aclaris Therapeutics during the first quarter worth about $21,116,000. Finally, Westfield Capital Management Co. LP raised its position in Aclaris Therapeutics by 55.2% in the first quarter. Westfield Capital Management Co. LP now owns 695,502 shares of the biotechnology company’s stock worth $20,740,000 after buying an additional 247,287 shares during the last quarter. 88.64% of the stock is currently owned by hedge funds and other institutional investors.

Aclaris Therapeutics, Inc. (NASDAQ ACRS) opened at 26.97 on Thursday. The stock’s market cap is $720.99 million. The company has a 50-day moving average price of $27.89 and a 200-day moving average price of $27.99. Aclaris Therapeutics, Inc. has a 52 week low of $18.24 and a 52 week high of $33.25.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.12. Analysts anticipate that Aclaris Therapeutics, Inc. will post ($3.15) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: “Aclaris Therapeutics, Inc. (ACRS) Shares Sold by Rothschild Asset Management Inc.” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://www.thecerbatgem.com/2017/08/10/aclaris-therapeutics-inc-acrs-shares-sold-by-rothschild-asset-management-inc.html.

A number of research analysts recently issued reports on ACRS shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $36.00 target price on shares of Aclaris Therapeutics in a report on Wednesday, June 28th. BidaskClub raised Aclaris Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, July 24th. Cantor Fitzgerald set a $50.00 target price on Aclaris Therapeutics and gave the stock a “buy” rating in a report on Wednesday. ValuEngine lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, June 6th. Finally, Guggenheim reissued a “buy” rating and issued a $40.00 price target on shares of Aclaris Therapeutics in a research note on Tuesday, July 4th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $39.00.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to address the needs in dermatology. Its lead drug candidate, A-101 Topical Solution, is a hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis (SK).

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics, Inc. (NASDAQ:ACRS).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Stock Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related stocks with our FREE daily email newsletter.